AAM
RXRX icon

Azzad Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Azzad Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,236
Closed -$52.9K – 377
2026
Q1 		$52.9K Buy
17,236
+2,828
+20% +$10.9K 0.01% 328
2025
Q4 		$58.9K Sell
14,408
-408
-3% -$2.02K 0.01% 327
2025
Q3 		$72.3K Sell
14,816
-1,252
-8% -$6.58K 0.01% 322
2025
Q2 		$81.3K Sell
16,068
-743
-4% -$3.65K 0.01% 307
2025
Q1 		$88.9K Buy
16,811
+2,982
+22% +$21.7K 0.01% 298
2024
Q4 		$93.5K Sell
13,829
-1,168
-8% -$7.85K 0.02% 169
2024
Q3 		$98.8K Sell
14,997
-828
-5% -$5.94K 0.01% 301
2024
Q2 		$119K Sell
15,825
-367
-2% -$3.2K 0.01% 292
2024
Q1 		$161K Buy
+16,192
New +$180K 0.02% 295

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Azzad Asset Management's RXRX Position: Q2 2026 in Review

Azzad Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 17,236 shares — an estimated $52.9K sold.

Azzad Asset Management first reported a position in RXRX in Q1 2024 and held it in 9 quarters. The position peaked at $161K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Azzad Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Azzad Asset Management sold 17,236 Recursion Pharmaceuticals shares in Q2 2026, an estimated $52.9K.
  • Azzad Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • Azzad Asset Management's Recursion Pharmaceuticals position peaked at $161K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Azzad Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.